Essilor Stellest 2.0 Interim Trial Shows Strong Myopia Control; AI Lens Design Updates Announced
Stellest 2.0 six-month trial results, AI in design, and dry eye treatments
EssilorLuxottica released six-month interim results from a randomized, double-masked trial evaluating Essilor Stellest 2.0 lenses in children with myopia. The study found average treatment effects of 0.51D for myopia progression and 0.21mm for axial elongation compared to single vision controls. Charlotte Timbury, director of medical and professional affairs for North Europe, noted that these results are comparable to one year of first-generation lens wear. Patient adaptation was high, with 98% of children fully adapting within one week and no drop-outs reported. The design features increased mean power and asphericity across lenslets plus an extra ring of lenslets, while maintaining a 9mm central zone for easier switching from previous generations. Additionally, Essilor announced a new dynamic AI design system for its Varilux XR series, enhancing customization based on evolving visual behaviors.
Source:Optometry Today · aop.org.uk